Get the Stockscreener App
195.21
0.72%
1.39
After Hours:
195.21
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $195.21, with a volume of 871.30K.
It is up +0.72% in the last 24 hours and down -4.31% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$193.82
Open:
$193.99
24h Volume:
871.30K
Relative Volume:
0.98
Market Cap:
$21.61B
Revenue:
$11.28B
Net Income/Loss:
$1.07B
P/E Ratio:
21.53
EPS:
9.0657
Net Cash Flow:
$1.33B
1W Performance:
+4.61%
1M Performance:
-4.31%
6M Performance:
+2.07%
1Y Performance:
+15.09%
1-Day Range:
$193.96
$196.92
1-Week Range:
$187.06
$196.92
52-Week Range:
$164.65
$213.50
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
195.21 | 21.46B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-25-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-02-25 | Initiated | Redburn Atlantic | Buy |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
Quest Diagnostics Stock: Analyst Estimates & Ratings - Barchart.com
Quest Diagnostics 8-K SEC Filing May 2026: Shareholder Vote Results and Company Information - Minichart
Quest Diagnostics (DGX) Announces Results of 2026 Annual Meeting of Stockholders - GuruFocus
Quest Diagnostics shareholders elect directors and approve auditor at annual meeting - Investing.com UK
Quest Diagnostics shareholders elect directors and approve auditor at annual meeting By Investing.com - Investing.com South Africa
Quest Diagnostics (DGX) director granted 1,142 restricted stock units in Form 4 filing - Stock Titan
Director at Quest Diagnostics (NYSE: DGX) receives 1,142 RSUs - Stock Titan
Quest Diagnostics (DGX) director receives 1,142-share restricted stock unit grant - Stock Titan
Quest Diagnostics (DGX) director gets 1,142-share restricted stock unit award - Stock Titan
Director Tracey Doi of Quest Diagnostics (DGX) receives 1,142-share equity award - Stock Titan
Director at Quest Diagnostics (DGX) awarded 1,142 restricted stock units - Stock Titan
Director at Quest Diagnostics (NYSE: DGX) receives 1,142 stock units - Stock Titan
Quest Diagnostics (DGX) director receives 1,142 restricted stock units - Stock Titan
Director at Quest Diagnostics (DGX) receives 1,142 share units - Stock Titan
Quest Diagnostics (NYSE: DGX) details 2026 shareholder votes on board, pay and auditor - Stock Titan
Why is Quest Diagnostics (DGX) down 5% since last earnings report? - MSN
Why Is Quest Diagnostics (DGX) Down 5% Since Last Earnings Report? - Yahoo Finance
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics Keeps Quarterly Dividend at $0.86 a Share, Payable July 22 to Holders of Record July 8 - marketscreener.com
Quest Diagnostics Declares Quarterly Cash Dividend - Barchart.com
Guardant Health’s Shield Blood-Based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics - Nevada Business Magazine
Is This the Right Time to Hold DGX Stock in Your Portfolio? - TradingView
Quest Diagnostics Incorporated announces Quarterly dividend, payable on July 22, 2026 - marketscreener.com
Baird Adjusts Price Target on Quest Diagnostics to $232 From $229, Maintains Neutral Rating - Moomoo
Quest Diagnostics (NYSE:DGX): A Solid Dividend Play Backed by Strong Profitability and Financial Health - ChartMill
International Assets Investment Management LLC Purchases New Shares in Quest Diagnostics Incorporated $DGX - MarketBeat
Q2 EPS Estimates for Quest Diagnostics Cut by Zacks Research - MarketBeat
173,262 Shares in Quest Diagnostics Incorporated $DGX Bought by Conning Inc. - MarketBeat
How The Investment Narrative For Quest Diagnostics (DGX) Is Shifting With New Valuation Work - Yahoo Finance
Quest Diagnostics Incorporated (NYSE:DGX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Global HPV Testing and Pap Test Market is Expected to Showcase a Significant Growth at a CAGR of ~7% by 2034 | DelveInsight - GlobeNewswire Inc.
Quest Diagnostics Incorporated $DGX Shares Acquired by Ethic Inc. - MarketBeat
Truist Financial Corp Cuts Stock Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Swedbank AB Increases Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Generali Asset Management SPA SGR Purchases 8,924 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc. stock underperforms Friday when compared to competitors - MarketWatch
Quest Diagnostics (NYSE: DGX) sells $500M in 5.000% senior notes due 2036 - Stock Titan
Bullish Quarterly Results: 3 Companies Raising Guidance - TradingView
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term - Yahoo Finance
DGX SEC FilingsQuest Diagnostics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
DGX6380050 Bond Analysis — Key Metrics - TradingView
Quest Diagnostics Incorporated $DGX Shares Sold by Keybank National Association OH - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Acquired by Davis Selected Advisers - MarketBeat
Quest Diagnostics Incorporated $DGX Stock Holdings Increased by Artemis Investment Management LLP - MarketBeat
Quest Diagnostics | 8-K: Current report - Moomoo
Quest Diagnostics Incorporated (NYSE:DGX) Short Interest Update - MarketBeat
Quest Diagnostics prices $500M 5.00% senior notes due 2036 to fund general purposes - TradingView
[8-K] QUEST DIAGNOSTICS INC Reports Material Event - Stock Titan
Quest Diagnostics Incorporated $DGX Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Sold by Danica Pension Livsforsikringsaktieselskab - MarketBeat
Quest Diagnostics | SCHEDULE 13G: Others - Moomoo
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
1.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):